非小细胞肺癌表皮生长因子受体20外显子插入突变四例报道并文献复习

Insertion Mutation in Exon 20 of Epidermal Growth Factor Receptor in Non-small Cell Lung Cancer:4 Cases Report and Literature Review

肺癌占恶性肿瘤发病率第一位,在亚裔非吸烟肺腺癌女性中,表皮生长因子受体(EGFR)是最常见的突变基因,其中约90%的EGFR突变是19外显子典型框内突变或21外显子L858R点突变,其次为20外显子插入突变。不同突变患者的治疗方法及其从酪氨酸激酶抑制剂(TKI)治疗中的获益不同。本文报道4例非小细胞肺癌EGFR 20外显子插入突变患者,并对EGFR 20外显子插入突变相关文献进行复习,以为此类患者的治疗提供思路。

Lung cancer accounts for the first in the incidence rate of malignant tumors.In Asian non-smoking women with lung adenocarcinoma,epidermal growth factor receptor(EGFR)is the most common mutation gene.About 90%of EGFR mutations are typical intron mutation in 19 exons or 21 exon L858 R point mutation,followed by 20 exon insertion mutation.The treatment of patients with different mutations and their benefits from tyrosine kinase inhibitor(TKI)treatment are different.This article reported 4 cases of patients with EGFR 20 exon insertion mutations,and reviewed relevant literature on EGFR 20 exon insertion mutations,so as to provide ideas for the treatment of such patients.